Elizabeth Schneider: Revolutionary Drug Shows Promise for Primary Ovarian Insufficiency
Elizabeth Schneider, Staff Product Marketing Manager at Illumina, shared a post on LinkedIn:
“Primary ovarian insufficiency (POI), in which the ovaries don’t mature and release eggs properly, affects about 3% of women under age 40 and typically causes infertility. But a drug already approved to treat kidney disease may one day help some of these people get pregnant, a research team reports today in Science.
In studies of mouse ovarian tissue and live mice, the drug, called finerenone, kick-started the growth of tiny egg-containing sacs, or follicles—a process that’s often defunct in people with POI. In a small clinical trial, people with POI who were given the drug went on to produce mature eggs that could be harvested, and some of the eggs were then successfully fertilized in the lab.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
May 24, 2026, 19:45Danielle Uses Her Voice and Story to Help Create Change – Preeclampsia Foundation
-
May 24, 2026, 19:42Jakub Dejewski: Looking Back at The Fertility Show at Olympia London
-
May 24, 2026, 09:50Sima Alnamoora: Day 5 Early Hatching Blastocyst Captured During IVF Cycle Monitoring
-
May 24, 2026, 07:29Lucile Ferreux: The Hidden Reality of Male Fertility, Have You Ever Had a Spermiogram?
-
May 24, 2026, 07:25Cesar Fertility Newsletter Highlights Lifestyle Impact on Male Fertility Awareness – Cesar Fertility
-
May 24, 2026, 07:21Carla Wicks: Understanding Racial Differences in Endometriosis Care Pathways
-
May 24, 2026, 07:14Why Do French Men Go 20 to 30 Years Without Any Genital Examination? – Cesar Fertility
-
May 24, 2026, 07:11Lucile Ferreux: Sperm Racing Event Sparks Debate on Male Fertility Awareness and Scientific Accuracy
-
May 24, 2026, 07:08Unlocking the Black Box of Implantation Failure with Multi-Dimensional AI in IVF – Santaan Fertility Center and Research Institute